AViTA Corporation (TPEX:4735)
Taiwan · Delayed Price · Currency is TWD 35.00
0.00 (0.00%)
Jul 17, 2025, 1:17 PM CST
AViTA Revenue
AViTA had revenue of 198.53M TWD in the quarter ending March 31, 2025, with 1.75% growth. This brings the company's revenue in the last twelve months to 930.71M, up 13.72% year-over-year. In the year 2024, AViTA had annual revenue of 927.30M with 5.48% growth.
Revenue (ttm)
930.71M
Revenue Growth
+13.72%
P/S Ratio
1.48
Revenue / Employee
11.08M
Employees
84
Market Cap
1.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 927.30M | 48.22M | 5.48% |
| Dec 31, 2023 | 879.08M | -321.84M | -26.80% |
| Dec 31, 2022 | 1.20B | -1.12B | -48.35% |
| Dec 31, 2021 | 2.33B | -274.96M | -10.57% |
| Dec 31, 2020 | 2.60B | 1.35B | 108.41% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 40.47M |
| PharmaEssentia | 11.34B |
| Bora Pharmaceuticals Co., LTD. | 20.87B |
| Lotus Pharmaceutical | 19.12B |
| Oneness Biotech | 117.33M |
| Polaris Group | 87.67M |
| Center Laboratories | 1.63B |
| Lumosa Therapeutics | 43.59M |